Abstract AB0640 Figure 1. Kaplan-Meier curves for 5-years survival in SSc patients (Log-rank 33.40, $p < 0.001$). Abbreviations: No H/L: absence of heart or lung involvement; ILD: interstitial lung disease; PH-ILD: Pulmonary hypertension associated to ILD; PAH: pulmonary arterial hypertension.

Table I. Statistically significant prognostic factors for 5-years mortality at univariate and multivariate analysis (Cox proportional hazards modelling).

	UNIVARIATE ANALYSIS			MULTIVARIATE ANALYSIS		
	HR	95%CI	P	HR	95%CI	P
dcSSc	3.45	1.33-8.95	0.01	4.02	1.86-8.71	0.0001
Age at diagnosis	2.63	1.01-6.75	0.04	2.71	1.12-6.61	0.03
Delay in referral	2.64	1.00-6.84	0.05	2.73	1.11-6.7	0.03
BMI	0.90	0.82-0.99	0.03	0.91	0.84-0.98	0.02
No H/L Involvement	0.45	0.21-0.97	0.04	0.17	0.06-0.5	0.001

Abbreviations: dcSSc: diffuse cutaneous involvement; BMI: body mass index; H/L: heart or lung involvement; HR: hazard risk.

Disclosure of Interests: Fabio Cacciapaglia: None declared, Marco Fornaro: None declared, Fabio Montini: None declared, Livio Urso: None declared, Sergio Colella: None declared, Laura Coladonato: None declared, Maria Grazia Anelli: None declared, Emanuela Praino: None declared, Giuseppe Lopalco Speakers bureau: SOBI, BMS, Florenzo Iannone Consultant for: F Iannone has received consultancy fees and/or speaker honoraria from Pfizer, AbbVie, MSD, BMS, Novartis, Lilly, UCB outside this work, Speakers bureau: F Iannone has received consultancy fees and/or speaker honoraria from Pfizer, AbbVie, MSD, BMS, Novartis, Lilly, UCB outside this work

DOI: 10.1136/annrheumdis-2019-eular.5058

AB0641 VITAMIN D SERUM LEVELS AND THE RISK OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A LONGITUDINAL STUDY

Cristian Caimmi, Eugenia Bertoldo, Alice Pozza, Paola Caramaschi, Giovanni Orsolini, Davide Gatti, Maurizio Rossini, Ombretta Viapiana. Rheumatology Unit, University of Verona, Verona, Italy

Background: Vitamin D is known to influence the immune system in many different diseases although longitudinal studies on systemic sclerosis (SSc) are still missing.

Objectives: this study wants to investigate if variations in vitamin D serum levels (25OHD) over time affect digital ulcers (DU) in SSc.

Methods: this is a retrospective study on 65 patients. Data on disease characteristics and 25OHD were collected in 2011 and 2016.

Results: The mean age of our cohort was 58 (12) years with a mean disease duration of 9.5 (5.3) years. Most of our patients had a limited subset (69.2%). At baseline 50.8% and 41.5% after 5 years had 25OHD < 30 ng/mL. Supplemented patients (8750 IU/week) at baseline were 39 (60.0%) and 45 (69.2%) at the end of follow up. Nevertheless, 31 (47.7%) had a decrease of 25OHD in 5 years. In univariate analysis, patients with incident digital ulcers (DU) had a decrease in 25OHD as compared to patients with no incident DU (-17.4 (37.0) vs. 13.0 (89.5), $p = 0.018$). No differences in 25OHD variations were found for other disease characteristics. In multivariate analysis correcting for previous DU and mRSS at baseline, patients with a decrease in 25OHD had an increased risk of developing DU (OR (IC95%): 16.6 (1.7 to 164.5), $p = 0.017$).

Conclusion: In this study we have shown that a decrease in 25OHD increases the risk of developing DUs and that vitamin D supplementation with the doses currently recommended may be insufficient in SSc. Further studies in wider cohorts are needed to confirm these results and to evaluate the effectiveness of a more aggressive or different vitamin D supplementation.

Disclosure of Interests: Cristian Caimmi: None declared, Eugenia Bertoldo: None declared, Alice Pozza: None declared, Paola Caramaschi: None declared, Giovanni Orsolini Speakers bureau: Grunenthal, Davide Gatti Speakers bureau: Abiogen, Amgen, Janssen-Cilag, Mundipharma, Pfizer, Maurizio Rossini: None declared, Ombretta Viapiana Speakers bureau: Novartis, Abbvie, Eli-Lilly, Sanofi Genzyme

DOI: 10.1136/annrheumdis-2019-eular.5318

AB0642 DESCRIPTION OF SAE1/2 ANTIBODY IN A DERMATOMYOSITIS COHORT

Jordi Camins-Fàbregas¹, Clara Esteve-Cols², Ivette Casafont-Solé¹, Melania Martínez-Morillo¹, María Aparicio-Espinar¹, Lourdes Mateo¹, Anne Riveros¹, Laia Gifre¹, Clara Sangüesa-Gomez¹, Águeda Prior-Español¹, Annika Nack¹, Anahy Brandy-García¹, Monica Munera-Campos³, Isabel Bielsa-Marsol³, Eva Martínez-Cáceres¹, Alejandro Olive¹, Bibiana Quirant², Susana Holgado^{1,2}. ¹Hospital Universitari Germans Trias i Pujol, Rheumatology, Badalona, Spain; ²Hospital Universitari Germans Trias i Pujol, Immunology, Badalona, Spain; ³Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain

Background: Myositis specific antibodies have gained special importance in last years. Its knowledge has allowed stratifying patients in different clinical phenotypes, predicting with greater accuracy prognosis and establishing a clinical attitude to follow. SAE1/2 antibody (anti-small ubiquitin-like modifier activating enzyme) was first described in 2007 in patients with amyopathic dermatomyositis with cutaneous and digestive involvement. Its prevalence ranges from 8% in European cohorts to 3% in Asians.

Objectives: Describing myositis specific antibodies (MSA) in a cohort of inflammatory myopathies. To characterize the clinical phenotype of SAE1/2 antibody and to compare it with the rest of MSA.

Methods: Patients diagnosed of dermatomyositis in a tertiary hospital from 1978-2018, according to the criteria of Bohan and Peter (1975) and according to Dalakas classification criteria (2015). Clinical and analytical data, including the immunological profile were collected, as well as the treatments received and the evolution of the disease.

Results: Out of 46, 41 dermatomyositis had positive antinuclear antibodies (ANA). 55% percent had ANA titles > 640 , being the fine speckled pattern the most frequent (43%) followed by coarse speckled and homogeneous (13.6% each).

72% had MSA, the most frequent being antiJo1 (27.3%) followed by MDA5 (18.2%) and SAE1/2 (15%). Up to 40% had two or more antibodies, being the association with antibodies Ro52 and Ro60, the most frequent.

5 patients presented positivity against SAE antibody. In comparison to the rest of MSA, 80% presented with cutaneous debut ($p = 0.00$), being the most frequent manifestations heliotrope erythema ($p = 0.00$), Gottron papules ($p = 0.10$) and skin rash ($p = 0.00$). 60% had pathological capillaroscopy compared to 15% ($p = 0.00$). Muscular balance was preserved in 60% of patients. Sixty percent had dysphagia vs 9% ($p = 0.00$). Two of them had lung involvement (alveolar hemorrhage and rapidly progressive pneumonitis). In comparison with SAE negative group, patients presented more pulmonary hypertension (44.5vs34 mmHg), without reaching significant differences. No significant differences were found between muscle enzyme levels' neither acute phase reactants.

As complications, one patient presented a myocarditis with quickly rapidly progressive pneumonitis that required high doses of corticotherapy and another one alveolar hemorrhage, which was treated the same way. All patients required corticotherapy at doses of mg/kg, requiring two of them to be treated with DMARDs (methotrexate and dolquine) and one of them with immunoglobulins due to cutaneous involvement.

Mortality rate was 40% due to rapidly progressive lung affection and cardiorespiratory arrest.

Conclusion: Higher prevalence of SAE1/2 antibody in our cohort may be explained due to the use of amplified myositis antibodies kit that specifically includes this antibody. These patients typically present with cutaneous involvement and dysphagia but also lung affection as a complication. Studies with larger samples should be performed in order to know the prognosis of this antibody specificity.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.3325